Focus on screening, not biomarkers

Bookmark and Share
Published: 14 Dec 2017
Views: 2101
Dr Hain Van Poppel - European Association of Urology, Arnhem, The Netherlands

Hain Van Poppel talks to ecancer at EAPM 2017 in Belfast.

He underlines the problems surrounding the costs and relatively low success of drug development in prostate cancer.

He believes strongly that there is not enough emphasis on screening, and too much focus on biomarkers.